Galectin-3 serum profile in patients with knee osteoarthrosis: association with the disease course

Authors

  • Oksana Humeniuk Scientific Research Institute of Rehabilitation of National Pirogov Memorial Medical University Khmelnytske shose str., 104, Vinnytsia, Ukraine, 21029 National Pirogov Memorial Medical University Pyrohova str., 56, Vinnytsia, Ukraine, 21018, Ukraine
  • Mykola Stanislavchuk National Pirogov Memorial Medical University Pyrohova str., 56, Vinnytsia, Ukraine, 21018, Ukraine https://orcid.org/0000-0001-8505-5999
  • Nataliia Zaichko National Pirogov Memorial Medical University Pyrohova str., 56, Vinnytsia, Ukraine, 21018, Ukraine https://orcid.org/0000-0003-1889-6151

DOI:

https://doi.org/10.15587/2519-4798.2018.127276

Keywords:

galectin-3, osteoarthritis, knee joint, gonarthrosis, Lequesne index, WOMAC, KOOS, HAQ

Abstract

Aim of the work was to study the level of galectin-3 in serum in patients with osteoarthrosis of knee joints and to evaluate its association with the course of the disease.

Materials and methods. We examined 141 patients with osteoarthrosis (OA) of knee joints (76.6% of women), an average age of 58.4 ± 7.91 years, a disease duration of 10.5 ± 6.50 years, an II-III radiological stage. 33.3% of patients had a combination of OA knee and hip joints. Diagnosis of OA was established on the basis of criteria ACR 1991 and recommendations EULAR (2010). The Lequesne algo-functional index, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Knee Injury and Osteoarthritis Outcome Score (KOOS) were determined. Functional disorders were evaluated by the Health Assessment Questionnaire (HAQ). The content of galectin-3 in the blood was determined by the enzyme-linked immuno sorbent assay.

Results. It has been established that in 75% of patients with OA of knee joints aberrant levels of galectin-3 in the blood are detected, including 44% of subjects with a registered high level of the index (>15.8 ng/ml). The weak associative relationships between the level of galectin-3 and the age of patients and the duration of OA were established. Among patients with aberrant levels of galectin-3, persons with severe clinical manifestations of OA appeared more often. The increase in the level of galectin-3 was associated with a significant increase in the pain syndrome and the deterioration of physical function by the indexes of Lequesne, WOMAC, KOOS, HAQ.

Conclusions. In patients with OA, the increase in the production of galectin-3 is a factor in the deterioration of the clinical course of the disease, the increase in pain syndrome and functional disorders. A close associative relationship was found between the level of galectin-3 and the clinical severity indexes of OA and the weak associative relationship between the level of galectin-3 and the age and duration of the disease

Author Biographies

Oksana Humeniuk, Scientific Research Institute of Rehabilitation of National Pirogov Memorial Medical University Khmelnytske shose str., 104, Vinnytsia, Ukraine, 21029 National Pirogov Memorial Medical University Pyrohova str., 56, Vinnytsia, Ukraine, 21018

Researcher

Department of Internal Medicine No.1

Mykola Stanislavchuk, National Pirogov Memorial Medical University Pyrohova str., 56, Vinnytsia, Ukraine, 21018

MD, Professor, Head of Department

Department of Internal Medicine No.1

Nataliia Zaichko, National Pirogov Memorial Medical University Pyrohova str., 56, Vinnytsia, Ukraine, 21018

MD, Professor, Head of Department

Department of Biological and General Chemistry

References

  1. Kovalenko, V. M., Bortkevych, O. P. (2011) Osteoartroz i bil: stan problemy [Osteoarthritis and pain: the condition of the problem]. Bol. Sustavy. Pozvonochnyk [Pain. Joints. Spine], 1 (1). Available at: http://www.mif-ua.com/archive/article/16189
  2. Stasenko, T. (2017) Osteoartroz: optymalnyi vybir dlya uspishnogo likuvannya [Osteoarthritis: the best choice for successful treatment]. Ukrayinskyi medychnyi chasopys [Ukrainian medical journal], 2 (118). Available at: https://www.umj.com.ua/article/107694/osteoartroz-optimalnij-vibir-dlya-uspishnogo-likuvannya
  3. Bruyere, O., Cooper, C., Pelletier, J.-P., Maheu, E., Rannou, F., Branco, J. et. al. (2016). A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis–From evidence-based medicine to the real-life setting. Seminars in Arthritis and Rheumatism, 45 (4), 3–11. doi: 10.1016/j.semarthrit.2015.11.010
  4. Johnson, V., Giuffre, B., Hunter, D. (2012). Osteoarthritis: What Does Imaging Tell Us about Its Etiology? Seminars in Musculoskeletal Radiology, 16 (5), 410–418. doi: 10.1055/s-0032-1329894
  5. Toegel, S., Bieder, D., Andre, S., Kayser, K., Walzer, S. M., Hobusch, G. et. al. (2014). Human osteoarthritic knee cartilage: fingerprinting of adhesion/growth-regulatory galectins in vitro and in situ indicates differential upregulation in severe degeneration. Histochemistry and Cell Biology, 142 (4), 373–388. doi: 10.1007/s00418-014-1234-x
  6. Weinmann, D., Schlangen, K., Andre, S., Schmidt, S., Walzer, S. M., Kubista, B. et. al. (2016). Galectin-3 Induces a Pro-degradative/inflammatory Gene Signature in Human Chondrocytes, Teaming Up with Galectin-1 in Osteoarthritis Pathogenesis. Scientific Reports, 6 (1). doi: 10.1038/srep39112
  7. Toegel, S., Bieder, D., Andre, S., Altmann, F., Walzer, S. M., Kaltner, H. et. al. (2013). Glycophenotyping of osteoarthritic cartilage and chondrocytes by RT-qPCR, mass spectrometry, histochemistry with plant/human lectins and lectin localization with a glycoprotein. Arthritis Research & Therapy, 15 (5), 147. doi: 10.1186/ar4330
  8. Janelle-Montcalm, A., Boileau, C., Poirier, F., Pelletier, J.-P., Guevremont, M., Duval, N. et. al. (2007). Extracellular localization of galectin-3 has a deleterious role in joint tissues. Arthritis Research & Therapy, 9 (1), 20. doi: 10.1186/ar2130
  9. Boileau, C., Poirier, F., Pelletier, J.-P., Guevremont, M., Duval, N., Martel-Pelletier, J., Reboul, P. (2007). Intracellular localisation of galectin-3 has a protective role in chondrocyte survival. Annals of the Rheumatic Diseases, 67 (2), 175–181. doi: 10.1136/ard.2006.066514
  10. Ezzat, M. H. M., El-Gammasy, T. M. A., Shaheen, K. Y. A., Osman, A. O. Y. (2011). Elevated production of galectin-3 is correlated with juvenile idiopathic arthritis disease activity, severity, and progression. International Journal of Rheumatic Diseases, 14 (4), 345–352. doi: 10.1111/j.1756-185x.2011.01632.x
  11. Issa, S. F., Duer, A., Ostergaard, M., Horslev-Petersen, K., Hetland, M. L., Hansen, M. S. et. al. (2017). Increased galectin-3 may serve as a serologic signature of pre-rheumatoid arthritis while markers of synovitis and cartilage do not differ between early undifferentiated arthritis subsets. Arthritis Research & Therapy, 19 (1), 80. doi: 10.1186/s13075-017-1282-4
  12. Altman, R. D. (1991). Criteria for the classification of clinical osteoarthritis. The Journal of Rheumatology, 18, 10–12.
  13. Zhang, W., Doherty, M., Peat, G., Bierma-Zeinstra, M. A., Arden, N. K., Bresnihan, B. et. al. (2010). EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Annals of the Rheumatic Diseases, 69 (3), 483–489. doi: 10.1136/ard.2009.113100
  14. Lequesne, M. G. (1997). The algofunctional indices for hip and knee osteoarthritis. The Journal of Rheumatology, 24 (4), 779–781.
  15. Bellamy, N., Buchanan, W., Goldsmith, C. et. al. (1988). Validation study of WOMAC: A Health Status instrument for measuring clinically importent patient relevant outcomes to antirheumatic drug therapy in patients with osteoarhritis of the hip or knee. The Journal of Rheumatology, 15 (12), 1833–1840.
  16. Roos, E. M., Roos, H. P., Lohmander, L. S., Ekdahl, C., Beynnon, B. D. (1998). Knee Injury and Osteoarthritis Outcome Score (KOOS)–Development of a Self-Administered Outcome Measure. Journal of Orthopaedic & Sports Physical Therapy, 28 (2), 88–96. doi: 10.2519/jospt.1998.28.2.88
  17. Bruce, B., Fries, J. F. (2003). The Stanford Health Assessment Questionnaire: Dimensions and Practical Applications // Health and Quality of Life Outcomes, 1 (1), 20. doi: 10.1186/1477-7525-1-20
  18. De Boer, R. A., van Veldhuisen, D. J., Gansevoort, R. T., Muller Kobold, A. C., van Gilst, W. H., Hillege, H. L. et. al. (2012). The fibrosis marker galectin-3 and outcome in the general population. Journal of Internal Medicine, 272 (1), 55–64. doi: 10.1111/j.1365-2796.2011.02476.x
  19. Krintus, M., Kozinski, M., Fabiszak, T., Kubica, J., Panteghini, M., Sypniewska, G. (2017). Establishing reference intervals for galectin-3 concentrations in serum requires careful consideration of its biological determinants. Clinical Biochemistry, 50 (10-11), 599–604. doi: 10.1016/j.clinbiochem.2017.03.015

Downloads

Published

2018-03-29

How to Cite

Humeniuk, O., Stanislavchuk, M., & Zaichko, N. (2018). Galectin-3 serum profile in patients with knee osteoarthrosis: association with the disease course. ScienceRise: Medical Science, (3 (23), 27–32. https://doi.org/10.15587/2519-4798.2018.127276

Issue

No. 3 (23) (2018)

Section

Medical Science

License

Copyright (c) 2018 Oksana Humeniuk, Mykola Stanislavchuk, Nataliia Zaichko

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.

Authors, who are published in this journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.

 2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.